Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx-To-OTC Switch Flips On With June Public Forum, July NDAC Meeting

This article was originally published in The Tan Sheet

Executive Summary

The suitability of specific Rx drug classes - such as antihypertensive agents, osteoporosis treatments and oral contraceptives - for OTC use will be examined by FDA at a June 28-29 meeting in Gaithersburg, Md.
Advertisement

Related Content

OTC Cholesterol Drugs Preferred Over Supplements, NCL Survey Finds
OTC Cholesterol Drugs Preferred Over Supplements, NCL Survey Finds
OTC Cholesterol Drugs Preferred Over Supplements, NCL Survey Finds
OTC Switch Criteria For Chronic Illnesses, Risk Factors Differ - DeLap
Rx-To-OTC Switch Consumer Costs Study 'Flawed' - CHPA
Merck, BMS Prepare To Seek FDA Reversal On OTC Cholesterol Drugs
Cholesterol drug reviews
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
Flexeril Indications Self-Diagnosis Seen As Significant Hurdle By Committee
Flexeril Indications Self-Diagnosis Seen As Significant Hurdle By Committee

Topics

Advertisement
UsernamePublicRestriction

Register

PS091164

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel